Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

Overview of attention for article published in Trials, August 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)

Mentioned by

news: 3 news outlets
blogs: 1 blog

twitter: 20 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 39 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Imperial celebrates new professors | Imperial News

News Anyway, 25 Sep 2022

Annual academic promotions round sees over 130 academics becoming senior lecturers, readers and professors.

Imperial celebrates new professors

Imperial College London, 23 Sep 2022

Annual academic promotions round sees over 130 academics becoming senior lecturers, readers and professors.

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments.

Alzforum, 05 Aug 2022

Hoang K, Watt H, Golemme M, Perry RJ, Ritchie C, Wilson D, Pickett J, Fox C, Howard R, Malhotra PA.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.